Automatic Web Traffic Generator

Norepinephrine Depletion in Idiopathic Orthostatic Hypotension

HERMES A. KONTOS, M.D., Ph.D., F.A.C.P.; DAVID W. RICHARDSON, M.D., F.A.C.P.; JOHN E. NORVELL, Ph.D. Five patients with idiopathic orthostatic hypotension and defective vasoconstrictor responses to th... read more

Chelsea Therapeutics Announces Advancements in Neurogenic Orthostatic Hypotension Registration Program

FDA Confirms Special Protocol Assessment for Study 301 Protocol for Study 306 Finalized, Study to Begin in the Second Quarter Northera Selected as US Brand Name for Droxidopa in Neurogenic Orthostatic ... read more

Is Chelsea Therapeutics A Buy After Skyrocketing Up Over 150%?

By increasing the supply of norepinephrine available for delivery to its receptors, droxidopa may improve orthostatic blood pressure and alleviate symptoms of orthostatic hypotension ... as dopamine b... read more

Droxidopa for Symptomatic Neurogenic Hypotension

synthetic amino acid precursor of norepinephrine that received accelerated Food and Drug Administration approval in February 2014 after Orphan Drug status for a debilitating condition known as symptom... read more

Chelsea Therapeutics submits NDA to market NORTHERA for NOH treatment

seeking approval to market NORTHERA™ (droxidopa), an orally active synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension, NOH, in patients with pri... read more

Chelsea announces positive results from combined Northera data phase III trials in Neurogenic OH patients

The results, which include data from over 250 patients with symptomatic Neurogenic OH and diagnoses of Parkinson's disease, multiple system atrophy (MSA), pure autonomic failure (PAF), dopamine beta h... read more

Diabetes sparks a rise in neuropathy

Others who should do so include people with vitamin deficiency ... For autonomic neuropathy, medications can be used to help regulate the bodily functions that are no longer working as they should, su... read more

Lundbeck agrees $658m deal to buy Chelsea Therapeutics

Denmark's Lundbeck has boosted its neurology ... approved to treat symptomatic neurogenic orthostatic hypotension (NOH), a disorder caused by failure to produce and or release adequate amounts of nore... read more

THE PHARMACOLOGY OF ADRENERGIC RECEPTORS

Drugs such as Guanethidine can inhibit the Ca 2+-dependent release of norepinephrine, thus having a sympatholytic effect. Drugs such as Reserpine cause the destruction of storage granules, and as a re... read more

Chelsea Therapeutics Receives Special Protocol Assessment for Pivotal Phase 3 Study of Droxidopa in Neurogenic Orthostatic Hypotension

About Droxidopa and Symptomatic Neurogenic Orthostatic Hypotension ... a deficient release of norepinephrine, the neurotransmitter used by sympathetic autonomic nerves to send signals to the blood ves... read more

Chelsea gets new patent for use of droxidopa in fibromyalgia

Droxidopa, a synthetic amino acid, is converted by the body into norepinephrine and, as a prodrug of NE, provides replacement therapy for NE deficiency ... the treatment of symptomatic Neurogenic Orth... read more

Postural orthostatic tachycardia syndrome is associated with platelet storage pool deficiency

Abstract: Mechanisms have been postulated to explain postural orthostatic tachycardia syndrome (POTS), however ... during the first 10 minutes of upright posture without orthostatic hypotension, weakn... read more